Cancer Developer Y-mABS Raises $96 Million in IPO

As reported in Xconomy, Frank Vinluan writes that cancer drug developer Y-mAbs Therapeutics is the latest biotech company to go public, raising $96 million in its IPO. New York-based Y-mAbs priced its offering of 6 million shares at $16 each, which was the high end of...

Pin It on Pinterest